Complications of defibrillation.


Cardiac defibrillation is the process of administering a transthoracic electrical current to an individual who experiences one of the two lethal ventricular dysrhythmias, ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT).

Complications of defibrillation

The stored energy is immediately released when a patient is defibrillated. The shock is administered at whatever point the cardiac cycle happens to be in at that moment. If an electrical shock is given to someone who is not in VF or pulseless VT, it is possible for the energy to be delivered during the relative refractory period, which corresponds to the latter part of the T wave of the cardiac cycle. If an electrical charge were given at this crucial time, it might cause VF by the “R-on-T phenomenon”, leading to cardiac arrest in a patient who originally had a pulse. For this reason, defibrillation is only performed for VF or pulseless VT. Synchronised cardioversion is performed rather than defibrillation to avoid this complication when a patient is not in cardiac arrest but needs electrical cardioversion for an unstable tachycardic rhythm. Synchronised cardioversion with a 100 Joules of energy dose is recommended for a patient with VT and a palpable pulse who also shows signs of hypoperfusion and haemodynamic instability.

How Physicians Perform Prehospital ECMO on the Streets of Paris


file
The ECPR response team in Paris implements ECMO on scene to restore blood flow to the body and limit ischemic consequences to the brain and coronary arteries.

A revolutionary on-scene response for patients in refractory out-of-hospital cardiac arrest

Extracorporeal cardiopulmonary resuscitation (ECPR) is the second line of treatment for out-of-hospital cardiac arrest (OHCA) not responding to usual BLS and ALS treatments (e.g., cardiac compressions/massage, ventilation, defibrillation, drug administration, etc.).

ECPR is now recommended by international guidelines in the management of refractory OHCA of suspected reversible cause, such as acute myocardial infarction, pulmonary embolism and intoxication.1

ECPR brings respiratory and circulatory support, ensuring sufficient blood and oxygen supply to the whole body, especially the brain. The hybrid implementation technique used by Service d’Aide Medical d’Urgence (SAMU) in Paris, which uses a surgical cutdown followed by insertion of the cannula in the femoral artery, is quick, safe and accessible to emergency physicians, with low failure rates compared with percutaneous cannulation.

The objective of ECPR is to perfuse the brain while the cause of the cardiac arrest is sought and treated at a specialty hospital (e.g., by coronary angiography, CT scan, etc.). Indeed, the primary objective is to obtain return of spontaneous circulation (ROSC), however, long-term survival depends on the neurological prognosis of the patient.

Once ECPR has been initiated, acceptable blood flow is restored to the whole body, and especially to the brain and coronary arteries in order to limit ischemic consequences. Many studies, both clinical and experimental, have shown that the blood flow delivered by ECPR is much higher than that delivered by mechanical compressions/cardiac massage. ECPR is therefore considered as a “bridge” in order to have time to treat the cause of the cardiac arrest. The international results of the utilization of the ECPR are very encouraging.2-4

SAMU DE PARIS

SAMU is a free public service in charge of responding to EMS calls in Paris. SAMU operates Department 75, a single medical dispatch center for the whole city of Paris. In the rest of the country, there’s one SAMU per department.

All calls to SAMU are screened by a doctor. The administrative information and reason of the call are initially taken by an assistant dispatcher who transfers the call to a dispatch doctor.

The doctor’s role is to give the most appropriate medical response depending on the reason of the call and the degree of severity and emergency: referring the patient to a general practitioner, sending a general practitioner to the patient’s home, directing the patient to the nearest ED, or dispatching the most appropriate means of transportation or care (i.e., an ambulance, a firefighter BLS unit or a mobile intensive care unit [MoICU]).

The French prehospital system is based on the possibility of a MoICU being sent out to the patient.

The MoICU is usually composed of three people: an emergency physician or anesthesiologist intensivist, a nurse and a paramedic.

The ambulance used by the MoICU contains everything a physician would need to treat an acute patient in hospital ED or ICU. This system is the opposite of the “scoop and run” concept, as we send the hospital to the patient in order to evaluate the patient on scene, make a diagnosis, stabilize and/or treat, and transport the patient directly to the most appropriate service. This could mean transporting straight to the catheterization lab for an acute myocardial infarction, to the ICU for a coma which has required intubation, or to the operation room for an unstable aortic dissection needing immediate surgery.

This system can do everything from “stay and treat,” such as prehospital ECPR, or “run and treat,” in the case of penetrating trauma for a damage control situation.

In the case of a call for a patient in cardiac arrest-witnessed or diagnosed over the phone-a BLS team, operated by the Paris Fire Brigade, is immediately dispatched along with the SAMU MoICU team. Dispatch guides the witness in bystander CPR over the phone.

The BLS team is usually first to arrive on scene, with a mean arrival time within nine minutes in Paris, followed by the MoICU team.

ALS is then delivered on scene until ROSC is obtained. Depending on the presumed etiology of the cardiac arrest, the patient can be taken directly to the catheterization lab for immediate coronary angiography, to CT or to the ICU. The dispatching of the ECPR team and decision-making in the case of a refractory cardiac arrest will be described later.

PREHOSPITAL ECPR

When the first disappointing results of in-hospital ECPR for OHCA were published (4% of survival in patients presenting refractory OHCA being brought to the hospital for ECPR implementation), the main reason found for these poor resuscitation results was the prolonged low-flow time period (between initiation of cardiac massage and ECPR pump flow).5

We found that one of the items contributing to this low flow period was extraction and transportation times to the hospital after failure of ALS to obtain ROSC. Indeed, in urban settings around the world, it’s often difficult for patients to be treated in the hospital within 45-60 minutes of cardiac arrest, even with a load and go strategy.6,7

To begin implementation much earlier, we decided to design a system where ECMO is available as a second line of treatment by a team equipped to treat the patient on scene (e.g., in the street, in the metro, in an apartment, etc.).

The ECPR program at the SAMU de Paris was established in 2011.9,10 Physicians were initially trained for percutaneous implementation, but progressively switched to the surgical hybrid technique due to difficulties with implementing ongoing cardiac massage.

The ECPR team was initially alerted and put on standby in cases of witnessed OHCA for patients under the age of 70, and the team could be requested after 10 minutes of unsuccessful ALS by the MoICU team.

Since 2015, the ECPR team has been available 24/7. The ECPR team is systematically dispatched immediately when a call comes in for witnessed cardiac arrest, at the same time as the BLS unit and MoICU. This is done to be able to start ECPR implementation early, after just 20 min of CPR with an AED, as recent studies have shown that 20 minutes seems to be the optimal time to switch from conventional CPR to ECPR. The team is secondarily canceled if ROSC occurs during ALS or if there’s no indication for ECPR.

The ECPR unit can also be requested by the MoICU doctor for patients where chest pain advances into cardiac arrest. The objective behind early dispatch and implementation is to activate the ECMO pump within 60 minutes of collapse.

During 2015, prehospital ECPR implementation was the default strategy, except if the cardiac arrest occurred in the ambulance or with a very short extraction and transport time allowing for in-hospital implementation.

The ECPR team can also be requested by the SAMU dispatch centers from other departments surrounding Paris. This requires a very early alert in order to organize and dispatch the team, especially if this requires the team to be sent out by helicopter.

With this strategy, patients previously too far to reach an ECPR center have become eligible, thus allowing greater equity of care. In this situation, the ideal low-flow time of 60 minutes is extended to 90 minutes.

The objective behind early dispatch and implementation of ECPR is to activate the ECMO pump within 60 minutes of collapse.

The objective behind early dispatch and implementation of ECPR is to activate the ECMO pump within 60 minutes of collapse.

STAFFING & PROTOCOLS

The mobile ECPR response team is available 24/7 and is staffed by three people: a physician (anesthetist-intensivist or emergency physician), an anesthetic nurse and a paramedic.

The physician is responsible for implementing ECPR according to SAMU’s hybrid surgical/Seldinger technique, assisted under “sterile” conditions by the first on-scene MoICU doctor first or another available assistant.

The anesthetic nurse is responsible for priming the ECMO machine during the implementation and then preparing necessary drugs with the help of the nurse from the MoICU. (Vasoactive drugs and sedation are systematically administered after ECPR initiation.)

The paramedic assists the physician during implementation, retrieving and handing the necessary equipment under sterile conditions.

Once the ECMO pump has been initiated and pump flow is satisfactory, the patient is transported to the hospital under strict monitoring and supervision, with the team paying close attention to the cannula, circuit, machine and operational and clinical parameters.

Before and during implementation, the ECPR physician coordinates information concerning patient extraction, ensuring acceptable mobilization positions for the patient, especially in case of difficult extraction.

Special protocols have been written to ensure the ECPR process flows at every level.

Call center protocol: A protocol exists in two parts. The first protocol dictates the dispatching of the ECPR team in the case of witnessed OHCA for patients under the age of 70 and receiving CPR.

A second protocol guides the steps once the indication of ECPR has been confirmed. In this case, one person in the dispatch center is dedicated to this case until the patient reaches the hospital.

This protocol includes coordination with other services: firefighters in charge of the BLS; police to escort the ECPR team; blood bank staff in cases where prehospital transfusion is needed, or where ICU or coronary angiography are indicated. All of these steps are checked and followed in real time.

On-scene protocols: Two protocols exist. One for the ECPR team, “how to do it,” and the different steps to follow. A second protocol addresses how the MoICU team should proceed once ECPR implementation has been decided. It includes the initiation of mechanical CPR, groin disinfection, drug preparation and limitation of epinephrine.

When SAMU dispatch centers outside of Paris request ECPR, the protocol ensures that the Paris ECPR response unit is dispatched early so that the team arrives on scene with limited delays.

On-scene ECMO protocols require that ECPR be implemented after just 20 minutes of CPR with an AED-the optimal time to switch from conventional CPR to ECPR according to recent studies.

On-scene ECMO protocols require that ECPR be implemented after just 20 minutes of CPR with an AED-the optimal time to switch from conventional CPR to ECPR according to recent studies.

Results from implementing on-scene ECMO show an increase in survival rate from 8-29% with acceptable neurological status.

RESULTS & NEXT STEPS

The prehospital ECPR response team follows a scientific program. The first phase was the publication of the safety and feasibility. The second phase of the research was published more recently, including comparing a series of patients during two successive periods.

As described previously, from 2011-2014, the ECPR team was sent out in the absence of ROSC after 10 min of ALS.

In 2015, the ECPR team was sent out at the same time as the MoICU, in order for the team to be on the scene as soon as possible and be able to initiate ECPR early in case of absence of ROSC after 20 minutes of professional CPR. The objective was to reduce the low flow period, which is clearly a prognostic factor for neurological outcome.

Patients eligible for ECPR were: witnessed cardiac arrest with no-flow (i.e., no CPR) time < 5 minutes; persistent ventricular fibrillation (v fib) or persistent signs of life. Results from implementing on-scene ECMO show an increase in survival rate from 8-29% with acceptable neurological status (CPC 1 and 2).11

The last step is the confirmation of the results by a randomized study. In 2016, a multicenter randomized study was commenced to compare in-hospital and prehospital ECPR implementation. Patients are randomized after confirmation of refractory cardiac arrest eligible to ECPR. This study will include around 200 patients (ClinicalTrials.gov identifier: NCT02527031).

The objective is to clearly show that prehospital ECPR by emergency physicians is possible inside and outside of Paris as well as in other metropolitan areas and more rural settings.

In Paris, prehospital ECPR is now a second line of treatment for refractory v fib cardiac arrest after the failure of conventional care. The results are encouraging, but need to be confirmed elsewhere.

Several other teams have been trained to follow the SAMU ECMO implementation technique. Lyon, another large city in France, and Madrid, the capital of Spain, have recently started ECPR programs that include prehospital ECMO. Additional systems in Brussels, Melbourne, London and cities in the United States are looking to start prehospital ECPR programs, some expecting to begin treating patients in the field in 2018.

The Paris ECPR response team treats patients wherever they may be-from subway stations to streets to the famous Louvre Museum.

The Paris ECPR response team treats patients wherever they may be-from subway stations to streets to the famous Louvre Museum.

REFERENCES

1. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S444-S464.

2. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: An observational study and propensity analysis. Lancet. 2008;372(9638):554-561.

3. Stub D, Bernard S, Pellegrino V, et al. Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation. 2015;86:88-94.

4. Bellezzo JM, Shinar Z, Davis DP, et al. Emergency physician- initiated extracorporeal cardiopulmonary resuscitation. Resuscitation. 2012;83(8):966-970.

5. Le Guen M, Nicolas-Robin A, Carreira S, et al. Extracorporeal life support following out-of-hospital refractory cardiac arrest. Crit Care. 2011;15(1):R29.

6. Wang CH, Chou NK, Becker LB, et al. Improved outcome of extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest-A comparison with that for extracorporeal rescue for in-hospital cardiac arrest. Resuscitation. 2014;85(9):1219-1224.

7. Poppe M, Weiser C, Holzer M, et al. The incidence of “load & go” out-of-hospital cardiac arrest candidates for emergency department utilization of emergency extracorporeal life support: A one-year review. Resuscitation. 2015;91:131-136.

8. Kagawa E, Inoue I, Kawagoe T, et al. Assessment of outcomes and differences between in- and out-of-hospital cardiac arrest patients treated with cardiopulmonary resuscitation using extracorporeal life support. Resuscitation. 2010;81(8):968-973.

9. Lamhaut L, Jouffroy R, Kalpodjian A, et al. Successful treatment of refractory cardiac arrest by emergency physicians using pre-hospital ECLS. Resuscitation. 2012;83(8):e177-178.

10. Lamhaut L, Jouffroy R, Soldan M, et al. Safety and feasibility of prehospital extra corporeal life support implementation by non-surgeons for out-of-hospital refractory cardiac arrest. Resuscitation. 2013;84(11):1525-1529.

11. Lamhaut L, Hutin A, Puymirat E, et al. A pre-hospital extracorporeal cardio pulmonary resuscitation (ECPR) strategy for treatment of refractory out hospital cardiac arrest: An observational study and propensity analysis. Resuscitation. 2017;117:109-117.

Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation.


BACKGROUND

Many patients requiring pacemaker or implantable cardioverter–defibrillator (ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events, guidelines recommend bridging therapy with heparin; however, case series suggest that it may be safe to perform surgery without interrupting warfarin treatment. There have been few results from clinical trials to support the safety and efficacy of this approach.

METHODS

We randomly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfarin treatment or to bridging therapy with heparin. The primary outcome was clinically significant device-pocket hematoma, which was defined as device-pocket hematoma that necessitated prolonged hospitalization, interruption of anticoagulation therapy, or further surgery (e.g., hematoma evacuation).

RESULTS

The data and safety monitoring board recommended termination of the trial after the second prespecified interim analysis. Clinically significant device-pocket hematoma occurred in 12 of 343 patients (3.5%) in the continued-warfarin group, as compared with 54 of 338 (16.0%) in the heparin-bridging group (relative risk, 0.19; 95% confidence interval, 0.10 to 0.36; P<0.001). Major surgical and thromboembolic complications were rare and did not differ significantly between the study groups. They included one episode of cardiac tamponade and one myocardial infarction in the heparin-bridging group and one stroke and one transient ischemic attack in the continued-warfarin group.

CONCLUSIONS

As compared with bridging therapy with heparin, a strategy of continued warfarin treatment at the time of pacemaker or ICD surgery markedly reduced the incidence of clinically significant device-pocket hematoma.

Source: NEJM

 

Vigorous Sports OK for Some Patients with ICDs.


 

 

Many patients with implantable cardioverter-defibrillators (ICDs) can safely participate in vigorous sports, despite recommendations against such activity, a Circulation study finds.

Researchers followed nearly 400 athletes (aged 10 to 60) with ICDs for about 2.5 years; participants were involved in either organized or high-risk sports (most commonly, running, basketball, soccer, and skiing). Overall, no one experienced the primary endpoint, defined as tachyarrhythmic death, resuscitated tachyarrhythmia, or severe injury resulting from arrhythmia-related syncope or shock. Participants were not significantly more likely to receive shocks during sporting activities (10%) than during other recreational activities (8%). The ICD terminated all arrhythmia episodes.

The researchers conclude: “Many athletes with ICDs can engage in vigorous and competitive sports without physical injury or failure to terminate the arrhythmia. … These data provide a basis for more informed physician and patient decision making in terms of sports participation for athletes with ICDs.”

Soure: Circulation

 

St. Jude’s Riata Defibrillator Leads Again Under the Spotlight .


Patients may have concerns about their cardiac devices after reading a front-page New York Times story about St. Jude Medical‘s embattled Riata defibrillator leads. The leads were recalled in 2011 over the risk for failure associated with lead insulation abrasion.

The Times describes the dilemma now faced by cardiac device specialists and patients: take a potentially faulty lead out, or leave it in? Both strategies carry their own risks, the Times notes, although the FDA advises against preemptive lead removal. A study by the manufacturer suggests that 19% of Riata leads show signs of failing.

In August, the FDA recommended imaging studies for patients with Riata leads to check for possible failures. A specialist practicing near Chicago told the Times he was unaware of the FDA’s action until a reporter told him about it, adding that a St. Jude representative failed to mention the new guidance during a discussion late that month.

Source: New York Times